Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Recurrent chromosomal rearrangements have not been well characterized in common carcinomas. We used a bioinformatics approach to discover candidate oncogenic chromosomal aberrations on the basis of outlier gene expression. Two ETS transcription factors, ERG and ETV1 , were identified as outliers in prostate cancer. We identified recurrent gene fusions of the 5′ untranslated region of TMPRSS2 to ERG or ETV1 in prostate cancer tissues with outlier expression. By using fluorescence in situ hybridization, we demonstrated that 23 of 29 prostate cancer samples harbor rearrangements in ERG or ETV1 . Cell line experiments suggest that the androgen-responsive promoter elements of TMPRSS2 mediate the overexpression of ETS family members in prostate cancer. These results have implications in the development of carcinomas and the molecular diagnosis and treatment of prostate cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The high expression levels of ERG and PEA3 subfamily members in a subset of prostate tumors led to the discovery of common chromosomal rearrangements associated with this human cancer (36).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [36]
In the citing paper
“Chromosomal rearrangements that result in the overexpression of members of the PEA3 subfamily (ETV1, ETV4, or ETV5) are found less frequently (36, 170, 171).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [36]
In the citing paper
“Rearrangements of ETS loci are a hallmark of prostate cancer with ~50% of tumors showing alterations at an ETS gene locus (36).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [36]
Citations
Cites
ROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform
Rhodes, D. R., Yu, J., Shanker, K., Deshpande, N., Varambally, R., Ghosh, D., Barrette, T., Pander, A., & Chinnaiyan, A. M. (2004) · Neoplasia · doi:10.1016/s1476-5586(04)80047-2 · Cited by 3,612
Self-citationA census of human cancer genes
Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., & Stratton, M. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1299 · Cited by 3,184
Sotiriou, C., Neo, S.-Y., McShane, L. M., Korn, E. L., Long, P. M., Jazaeri, A., Martiat, P., Fox, S. B., Harris, A. L., & Liu, E. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732912100 · Cited by 1,993
Delineation of prognostic biomarkers in prostate cancer
Dhanasekaran, S. M., Barrette, T. R., Ghosh, D., Shah, R., Varambally, S., Kurachi, K., Pienta, K. J., Rubin, M. A., & Chinnaiyan, A. M. (2001) · Nature · doi:10.1038/35090585 · Cited by 1,673
Self-citationChromosomal translocations in human cancer
Rabbitts, T. H. (1994) · Nature · doi:10.1038/372143a0 · Cited by 1,503
Tian, E., Zhan, F., Walker, R., Rasmussen, E., Ma, Y., Barlogie, B., & Shaughnessy, J. D. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030847 · Cited by 1,503
A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia
Klein, A. D., Kessel, A. G. V., Grosveld, G., Bartram, C. R., Hagemeijer, A., Bootsma, D., Spurr, N. K., Heisterkamp, N., Groffen, J., & Stephenson, J. R. (1982) · Nature · doi:10.1038/300765a0 · Cited by 1,378
Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia
Valk, P. J. M., Verhaak, R. G. W., Beijen, M. A., Erpelinck, C. A. J., van Doorn-Khosrovani, S. B. V. W., Boer, J. M., Beverloo, H. B., Moorhouse, M. J., van der Spek, P. J., Löwenberg, B., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040465 · Cited by 1,370
Research works printed but not linked: 5
- I. S. Jeon et al., Oncogene10, 1229 (1995).
- B. Lin et al., Cancer Res.59, 4180 (1999).
- D. E. Afar et al., Cancer Res.61, 1686 (2001).
- S. M. Dhanasekaran et al., FASEB J.19, 243 (2005).
- J. B. Welsh et al., Cancer Res.61, 5974 (2001).
Cited by
Items 901–1,000 of 1,014
Rahim, S., Minas, T. Z., Hong, S.-H., Justvig, S., Çelik, H., Saygıdeğer, Y., Han, J. J., Kallarakal, A. T., Kong, Y., Rudek, M. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114260 · Cited by 68
Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications
Terada, N., Akamatsu, S., Kobayashi, T., Inoue, T., Ogawa, O., & Antonarakis, E. S. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017719215 · Cited by 74
Blee, A. M., He, Y., Yang, Y., Ye, Z., Yan, Y., Pan, Y., Ma, T., Dugdale, J. A., Kuehn, E., Kohli, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0653 · Cited by 74
Metabolomics Contributions to the Discovery of Prostate Cancer Biomarkers
Gómez-Cebrián, N., Rojas‐Benedicto, A., Albors-Vaquer, A., López‐Guerrero, J. A., Pineda‐Lucena, A., & Puchades‐Carrasco, L. (2019) · Metabolites · doi:10.3390/metabo9030048 · Cited by 74
Disparities in prostate cancer incidence and mortality rates: Solvable or not?
Badal, S. A. M., Aiken, W. D., Morrison, B. F., Valentine, H., Bryan, S., Gachii, A., & Ragin, C. C. R. (2019) · The Prostate · doi:10.1002/pros.23923 · Cited by 74
Schaefer, G., Mosquera, J. M., Ramoner, R. E., Park, K., Romanel, A., Steiner, E., Horninger, W., Bektić, J., Ladurner, M., Rubin, M. A., et al. (2013) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2013.4 · Cited by 74
Self-citationTherapy escape mechanisms in the malignant prostate
Santer, F. R., Erb, H. H. H., & McNeill, R. V. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.08.005 · Cited by 72
Font‐Tello, A., Juanpere-Rodero, N., de Muga, S., Lorenzo, M., Lorente, J. A., Fumadó, L., Serrano, L., Serrano, S., Lloreta, J., & Hernandez, S. F. (2015) · The Prostate · doi:10.1002/pros.23004 · Cited by 73
Knuuttila, M., Yatkin, E., Kallio, J., Savolainen, S., Laajala, T. D., Aittokallio, T. A., Oksala, R., Häkkinen, M. R., Keski‐Rahkonen, P., Auriola, S. O. K., et al. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.04.010 · Cited by 74
Reddy, E. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1014 · Cited by 76
Relevance of Fusion Genes in Pediatric Cancers: Toward Precision Medicine
Dupain, C., Harttrampf, A. C., Urbinati, G., Geoerger, B., & Massaad-Massade, L. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.01.005 · Cited by 73
Marked heterogeneity of ERG expression in large primary prostate cancers
Minner, S. J. P., Gärtner, M., Freudenthaler, F., Bauer, M., Kluth, M., Salomon, G., Hans Heinzer, A., Graefen, M., Bokemeyer, C., Simon, R., et al. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.130 · Cited by 66
New molecular biomarkers for the prognosis and management of prostate cancer--the post PSA era.
Bickers, B., & Hastie, C. (2009) · PubMed · Cited by 66
Rostad, K., Hellwinkel, O., Haukaas, S. A., HALVORSEN, O. J., Oyan, A. M., Haese, A., Budäus, L., ALBRECHT, H., Akslen, L. A., Schlomm, T., et al. (2009) · Apmis · doi:10.1111/j.1600-0463.2009.02517.x · Cited by 72
Expression of cancer/testis antigens in prostate cancer is associated with disease progression
Suyama, T., Shiraishi, T., Zeng, Y., Yu, W., Parekh, N., Vessella, R. L., Luo, J., Getzenberg, R. H., & Kulkarni, P. (2010) · The Prostate · doi:10.1002/pros.21214 · Cited by 66
Molecular Pathways: Targeting ETS Gene Fusions in Cancer
Feng, F. Y.-C., Brenner, J. C., Hussain, M., & Chinnaiyan, A. M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0275 · Cited by 76
Self-citationPatki, M., Chari, V., Sivakumaran, S., Gonit, M., Trumbly, R. J., & Ratnam, M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.438473 · Cited by 76
The role of epithelial plasticity in prostate cancer dissemination and treatment resistance
Bitting, R. L., Schaeffer, D., Somarelli, J. A., García-Blanco, M. A., & Armstrong, A. J. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9483-z · Cited by 71
Humoral Response Profiling Reveals Pathways to Prostate Cancer Progression
Taylor, B. S., Pal, M. K., Yu, J., Laxman, B., Sundaram, S. K., Zhao, R., Menon, A., Wei, J. T., Nesvizhskii, A. I., Ghosh, D., et al. (2007) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m700263-mcp200 · Cited by 69
Self-citationIntegrin-linked kinase as a target for ERG-mediated invasive properties in prostate cancer models
Becker‐Santos, D. D., Guo, Y., Ghaffari, M., Vickers, E. D., Lehman, M., Altamirano-Dimas, M., Oloumi, A., Furukawa, J., Sharma, M., Wang, Y. Z., et al. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs285 · Cited by 66
ERG rearrangement in small cell prostatic and lung cancer
Scheble, V. J., Braun, M., Wilbertz, T., Stiedl, A., Petersen, K., Schilling, D., Reischl, M., Seitz, G., Fend, F., Kristiansen, G., et al. (2010) · Histopathology · doi:10.1111/j.1365-2559.2010.03564.x · Cited by 66
Self-citationER stress drives Lipocalin 2 upregulation in prostate cancer cells in an NF-κB-dependent manner
Mahadevan, N. R., Rodvold, J. J., Almanza, G., Fernandez-Perez, A., Wheeler, M. C., & Zanetti, M. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-229 · Cited by 70
Linking DNA Damage and Hormone Signaling Pathways in Cancer
Schiewer, M. J., & Knudsen, K. E. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.02.004 · Cited by 69
Potu, H., Peterson, L. F., Kandarpa, M., Pal, A., Sun, H., Durham, A. B., Harms, P. W., Hollenhorst, P. C., Eskiocak, U., Talpaz, M., et al. (2017) · Nature Communications · doi:10.1038/ncomms14449 · Cited by 69
INTEGRATIVE BIOLOGY OF PROSTATE CANCER PROGRESSION
Tomlins, S. A., Rubin, M. A., & Chinnaiyan, A. M. (2006) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100047 · Cited by 66
Self-citationStructural basis of SARS-CoV-2 main protease inhibition by a broad-spectrum anti-coronaviral drug.
Wang, Y.-C., Yang, W., Yang, C., Hou, M., Tsai, C.-L., Chou, Y.-Z., Hung, M., & Chen, Y. (2020) · PubMed · Cited by 80
Galletti, G., Portella, L., Tagawa, S. T., Kirby, B. J., Giannakakou, P., & Nanus, D. M. (2014) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-014-0101-8 · Cited by 68
Expression profiling of CD133+ and CD133— epithelial cells from human prostate
Shepherd, C. J., Rizzo, S., Ledaki, I., Davies, M. C., Brewer, D. S., Attard, G., Bono, J. S. D., & Hudson, D. L. (2008) · The Prostate · doi:10.1002/pros.20765 · Cited by 70
Howarth, K., Blood, K. A., Ng, B. L., Beavis, J. C., Chua, Y. W., Cooke, S. L., Raby, S., Ichimura, K., Collins, V. P., Carter, N. P., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210993 · Cited by 65
CLEAN: CLustering Enrichment ANalysis
Freudenberg, J. M., Joshi, V. K., Hu, Z., & Medvedovic, M. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-234 · Cited by 64
ERG–SOX4 interaction promotes epithelial–mesenchymal transition in prostate cancer cells
Wang, L., Li, Y., Yang, X., Yuan, H., Li, X., Qi, M., Chang, Y. W. Y., Wang, C., Fu, W., Yang, M., et al. (2014) · The Prostate · doi:10.1002/pros.22783 · Cited by 66
Patterns of Chromosomal Aberrations in Solid Tumors
Grade, M., Difilippantonio, M. J., & Camps, J. (2015) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-20291-4_6 · Cited by 70
Koo, K. M., Wee, E. J. H., Mainwaring, P. N., Wang, Y., & Trau, M. (2016) · Small · doi:10.1002/smll.201602161 · Cited by 65
Jacobsen, F., Kraft, J., Schroeder, C., Hube‐Magg, C., Kluth, M., Lang, D. S., Simon, R., Sauter, G., Izbicki, J. R., Clauditz, T. S., et al. (2017) · Neoplasia · doi:10.1016/j.neo.2017.06.003 · Cited by 65
FOXF1 Defines the Core-Regulatory Circuitry in Gastrointestinal Stromal Tumor
Ran, L., Chen, Y., Sher, J. J., Wong, E. W. P., Murphy, D. A., Zhang, J. Q., Li, D., Denız, K., Sirota, I., Cao, Z., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0468 · Cited by 71
Predictive significance of TMRPSS2-ERG fusion in prostate cancer: a meta-analysis
Song, C., & Chen, H. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0672-2 · Cited by 69
Targeted treatment of prostate cancer
Wang, X., Yin, L., Rao, P., Stein, R. J., Harsch, K. M., Lee, Z., & Heston, W. D. W. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21491 · Cited by 73
“Furthermore, it has raised the possibility of targeting a specific oncogenic change, similar to those seen in hematological tumors [Tomlins et al., 2005].”
BackgroundResultEstablishment and Genomic Characterization of Mouse Xenografts of Human Primary Prostate Tumors
Priolo, C., Agostini, M., Vena, N., Ligon, A. H., Fiorentino, M., Shin, E., Farsetti, A., Pontecorvi, A., Sicińska, E., & Loda, M. F. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090873 · Cited by 64
Zeuschner, P., Linxweiler, J., & Junker, K. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1665998 · Cited by 67
Bao, R., Hernandez, K. M., Huang, L., & Luke, J. J. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001020 · Cited by 72
Shrestha, E., Coulter, J. B., Guzman, W., Özbek, B., Hess, M. M., Mummert, L. A., Ernst, S. E., Maynard, J. P., Meeker, A. K., Heaphy, C. M., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2018976118 · Cited by 65
“Depending on the population, up to 50% of prostate cancers harbor gene fusions between the androgen-regulated gene TMPRSS2 and erythroblast transformation–specific (ETS) transcription factor ERG, an alteration that leads to overexpression of the oncogenic transcription factor ERG (12, 13).”
BackgroundIdentification of TDRD1 as a direct target gene of ERG in primary prostate cancer
Boormans, J. L., Korsten, H., der Made, A. J. C. Z., van Leenders, G. J. L. H., de Vos, C., Jenster, G. W., & Trapman, J. (2013) · International Journal of Cancer · doi:10.1002/ijc.28025 · Cited by 64
Mounir, Z., Lin, F., Lin, V., Korn, J. M., Yu, Y., Valdez, R., Aina, O. H., Buchwalter, G., Jaffe, A. B., Korpal, M., et al. (2014) · Oncogene · doi:10.1038/onc.2014.308 · Cited by 65
Coactivator selective regulation of androgen receptor activity
Agoulnik, I. U., & Weigel, N. L. (2009) · Steroids · doi:10.1016/j.steroids.2009.02.007 · Cited by 69
The proto‐oncogene ERG is a target of micro RNA miR‐145in prostate cancer
Hart, M., Wach, S., Nolte, E., Szczyrba, J., Menon, R., Taubert, H. W., Hartmann, A., Stoehr, R., Wieland, W. F., Grässer, F. A., et al. (2013) · FEBS Journal · doi:10.1111/febs.12236 · Cited by 64
Prostate cancer of transition zone origin lacks TMPRSS2–ERG gene fusion
Guo, C. C., Zuo, G., Cao, D., Troncoso, P., & Czerniak, B. A. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.57 · Cited by 73
Discovery of prostate cancer biomarkers by microarray gene expression profiling
Sørensen, K. D., & Orntoft, T. F. (2009) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.09.74 · Cited by 65
Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications
Deng, Q., & Tang, D. G. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0217 · Cited by 64
“The E-twenty-six (Ets)-related gene (ERG), which is essential to maintain adult HSC self-renewal during stressinduced hematopoiesis (Loughran et al. 2008, Ng et al. 2011), is deregulated in most PCa through the most common genetic event TMPRSS2-ERG fusion (Tomlins et al. 2005, Mosquera et al. 2009).”
BackgroundPARP Inhibitors in Prostate Cancer
Geethakumari, P. R., Schiewer, M. J., Knudsen, K. E., & Kelly, W. K. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0480-2 · Cited by 74
Epigenetic Silencing of miRNA-338-5p and miRNA-421 Drives SPINK1-Positive Prostate Cancer
Bhatia, V., Yadav, A., Tiwari, R., Nigam, S., Goel, S., Carskadon, S. L., Gupta, N., Goel, A., Palanisamy, N., & Ateeq, B. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3230 · Cited by 67
Programmed Genome Rearrangements in the CiliateOxytricha
Yerlici, V. T., & Landweber, L. F. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.mdna3-0025-2014 · Cited by 67
Watanabe, H., Francis, J. M., Woo, M. S., Etemad, B., Lin, W., Fries, D. F., Peng, S., Snyder, E. L., Tata, P. R., Izzo, F., et al. (2013) · Genes & Development · doi:10.1101/gad.203208.112 · Cited by 69
Chimeric RNAs and their implications in cancer
Li, Z., Qin, F., & Li, H. (2017) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2017.10.002 · Cited by 66
Constitutive Activity of the Androgen Receptor
Chan, S. C., & Dehm, S. M. (2014) · Advances in pharmacology · doi:10.1016/b978-0-12-417197-8.00011-0 · Cited by 71
Molecular genetics of prostate cancer: emerging appreciation of genetic complexity
Barbieri, C. E., Demichelis, F., & Rubin, M. A. (2011) · Histopathology · doi:10.1111/j.1365-2559.2011.04041.x · Cited by 69
Self-citationZgoda, V. G., Kopylov, A. T., Tikhonova, O. V., Moisa, A. A., Pyndyk, N. V., Farafonova, T. E., Novikova, S. E., Лисица, А. В., Ponomarenko, E. A., Poverennaya, E. V., et al. (2012) · Journal of Proteome Research · doi:10.1021/pr300821n · Cited by 64
Yoshimoto, M., Ludkovski, O., DeGrace, D., Williams, J. L., Evans, A. J., Sircar, K., Bismar, T. A., Nuin, P. A. S., & Squire, J. A. (2011) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20939 · Cited by 64
Molecular Pathways: Targeting Resistance in the Androgen Receptor for Therapeutic Benefit
Mostaghel, E. A., Plymate, S. R., & Montgomery, B. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3601 · Cited by 69
EML4–ALK fusion transcript is not found in gastrointestinal and breast cancers
Fukuyoshi, Y., Inoue, H., Kita, Y., Utsunomiya, T., Ishida, T., & Mori, M. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604341 · Cited by 65
Clinical potential of the ERG oncoprotein in prostate cancer
Rosen, P., Sesterhenn, I. A., Brassell, S. A., McLeod, D. G., Srivastava, S. K., & Dobi, A. (2012) · Nature Reviews Urology · doi:10.1038/nrurol.2012.10 · Cited by 66
“Landmark studies have identified prevalent gene fusions in prostate cancer between genes encoding ETS transcription factors (predominantly ERG but also ETV1 , ETV4 , and ETV5 ) and promoter or other upstream sequences of androgen-inducible genes (predominantly TMPRSS2 but also SLC45A3 , NDRG1 , and C15orf21 )”
BackgroundIrshad, S., & Abate-Shen, C. T. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9409-1 · Cited by 67
CD44-SLC1A2 Gene Fusions in Gastric Cancer
Tao, J., Deng, N., Ramnarayanan, K., Huang, B., Oh, H. K., Leong, S. H., Lim, S. S., Tan, I. B., Ooi, C.-H., Wu, J., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001423 · Cited by 68
Battaglia, S., Maguire, O., Thorne, J. L., Hornung, L. B., Doig, C. L., Liu, S., Sucheston, L. E., Bianchi, A., Khanim, F. L., Gommersall, L. M., et al. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq086 · Cited by 66
Schweizer, M. T., & Antonarakis, E. S. (2012) · Therapeutic Advances in Urology · doi:10.1177/1756287212452196 · Cited by 68
Zhang, H., Ye, J., Weng, X., Liu, F., He, L., Zhou, D., & Liu, Y. (2015) · Cancer Genetics · doi:10.1016/j.cancergen.2015.06.002 · Cited by 75
Roudier, M. P., Winters, B. R., Coleman, I. M., Lam, H., Zhang, X., COLEMAN, R. T., Chery, L. J., True, L. D., Higano, C. S., Montgomery, B., et al. (2016) · The Prostate · doi:10.1002/pros.23171 · Cited by 63
Urine Exosomes for Non-Invasive Assessment of Gene Expression and Mutations of Prostate Cancer
Motamedinia, P., Scott, A., Bate, K., Sadeghi, N., Salazar, G., Shapiro, E. Y., Ahn, J. J., Lipsky, M., Lin, J. S., Hruby, G. W., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154507 · Cited by 63
Mechanisms of transcription factor evolution in Metazoa
Schmitz, J. F., Zimmer, F., & Bornberg‐Bauer, E. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw492 · Cited by 80
Identification of recurrent fusion genes across multiple cancer types
Yu, Y., Liu, P., Nelson, J. B., Hamilton, R. L., Bhargava, R., Michalopoulos, G. K., Chen, Q., Zhang, J., Ma, D., Pennathur, A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-38550-6 · Cited by 72
Androgen regulation of the androgen receptor coregulators
Urbanucci, A., Waltering, K. K., Suikki, H. E., Helenius, M. A., & Visakorpi, T. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-219 · Cited by 69
Towards rational and evidence‐based use of melatonin in prostate cancer prevention and treatment
Shiu, S. Y. W. (2007) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2007.00451.x · Cited by 63
Hollenhorst, P. C., Paul, L., Ferris, M. W., & Graves, B. J. (2010) · Genes & Cancer · doi:10.1177/1947601910395578 · Cited by 62
Rickman, D. S., Chen, Y.-B., Banerjee, S., Pan, Y., Yu, J., Vuong, T., Perner, S., Lafargue, C. J., Mertz, K. D., Setlur, S. R., et al. (2010) · Neoplasia · doi:10.1593/neo.10866 · Cited by 62
Self-citationPisano, C., Tucci, M., Stefano, R. F. D., Turco, F., Scagliotti, G. V., Maïo, M. D., & Buttigliero, C. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103185 · Cited by 63
Smith, A. M., Sewell, G. W., Levine, A. P., Chew, T. S., Dunne, J., O’Shea, N. R., Smith, P. J., Harrison, P. J., MacDonald, C., Bloom, S. L., et al. (2014) · Immunology · doi:10.1111/imm.12338 · Cited by 75
Immunohistochemical Endothelial Markers: A Review
Ordóǹez, N. G. (2012) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3182691c2a · Cited by 69
Ummanni, R., Barreto, F., Venz, S., Scharf, C., Barett, C., Mannsperger, H., Brase, J. C., Kuner, R., Schlomm, T., Sauter, G., et al. (2012) · Journal of Proteome Research · doi:10.1021/pr201172n · Cited by 62
Prostatic preneoplasia and beyond
Joshua, A. M., Evans, A., van der Kwast, T., Zieleńska, M., Meeker, A. K., Chinnaiyan, A. M., & Squire, J. A. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.12.001 · Cited by 82
Self-citationSonpavde, G., Attard, G., Bellmunt, J., Mason, M. D., Malavaud, B. A., TOMBAL, B. F., & Sternberg, C. N. (2011) · European Urology · doi:10.1016/j.eururo.2011.04.032 · Cited by 62
“A chromosomal rearrangement of the oncogenic ETS gene family resulting in the fusion of the androgen-regulated gene TMPRSS2 with ERG has been discovered in 40–70% of primary prostate cancers as well as in metastases and circulating tumour cells (CTCs) of men with CRPC [7,8].”
BackgroundSu, J., Yoon, B.-J., & Dougherty, E. R. (2010) · BMC Bioinformatics · doi:10.1186/1471-2105-11-s6-s8 · Cited by 72
Highly Specific Targeting of the TMPRSS2/ERG Fusion Gene Using Liposomal Nanovectors
Shao, L., Tekedereli, İ., Wang, J., Yuca, E., Tsang, S. V., Sood, A. K., Lopez‐Berestein, G., Özpolat, B., & Ittmann, M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2715 · Cited by 62
Molecular landscape of prostate cancer: Implications for current clinical trials
Khemlina, G., Ikeda, S., & Kurzrock, R. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.07.001 · Cited by 65
“[28–36] Pathway Function Examples of targeted agent”
BackgroundInfluentialInFusion: Advancing Discovery of Fusion Genes and Chimeric Transcripts from Deep RNA-Sequencing Data
Okonechnikov, K., Imai‐Matsushima, A., Paul, L., Seitz, A., Meyer, T. F., & García-Alcalde, F. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167417 · Cited by 73
Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
Stein, M., Patel, N., Bershadskiy, A., Sokoloff, A., & Singer, E. A. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.129133 · Cited by 67
Alexander, S. P. H., Armstrong, J. F., Davenport, A. P., Davies, J. A., Faccenda, E., Harding, S. D., Levi‐Schaffer, F., Maguire, J. J., Pawson, A. J., Southan, C., et al. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15094 · Cited by 64
Carmichael, C. L., Metcalf, D., Henley, K. J., Kruse, E. A., Di Rago, L., Mifsud, S., Alexander, W. S., & Kile, B. T. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213454109 · Cited by 61
TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas
Lotan, T. L., Toubaji, A., Albadine, R., Latour, M., Herawi, M., Meeker, A. K., Marzo, A. M. D., Platz, E. A., Epstein, J. I., & Netto, G. J. (2009) · Modern Pathology · doi:10.1038/modpathol.2008.236 · Cited by 61
Tumour markers in prostate cancer II: Diagnostic and prognostic cellular biomarkers
Bjartell, A. S., Montironi, R., Berney, D. M., & Egevad, L. (2011) · Acta Oncologica · doi:10.3109/0284186x.2010.531284 · Cited by 61
Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth
Mohamed, A. A. M., Xavier, C. P., Sukumar, G., Tan, S., Ravindranath, L., Seraj, N., Kumar, V., Sreenath, T., McLeod, D. G., Petrovics, G., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2949 · Cited by 61
Hellwig, B., Hengstler, J. G., Schmidt, M., Gehrmann, M. C., Schormann, W., & Rahnenführer, J. (2010) · BMC Bioinformatics · doi:10.1186/1471-2105-11-276 · Cited by 71
Liu, Q., Hu, Y., Stucky, A., Li, F., Zhong, J. F., & Wang, K. (2020) · BMC Genomics · doi:10.1186/s12864-020-07207-4 · Cited by 74
Emerging Principles in the Transcriptional Control by YAP and TAZ
Lopez-Hernandez, A., Sberna, S., & Campaner, S. (2021) · Cancers · doi:10.3390/cancers13164242 · Cited by 69
“Several observations support the oncogenic role of ERG and other ETS factors in prostate carcinogenesis [75].”
BackgroundCDX2-driven leukemogenesis involves KLF4 repression and deregulated PPARγ signaling
Faber, K., Bullinger, L., Ragu, C., Garding, A., Mertens, D., Miller, C., Martin, D., Walcher, D., Döhner, K., Döhner, H., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64745 · Cited by 55
Rcl is a novel ETV1/ER81 target gene upregulated in breast tumors
Shin, S., Bosc, D. G., Ingle, J. N., Spelsberg, T. C., & Janknecht, R. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21884 · Cited by 63
ERG Protein Expression in Human Tumors Detected With a Rabbit Monoclonal Antibody
Yaskiv, O., Rubin, B. P., He, H., Falzarano, S. M., Magi‐Galluzzi, C., & Zhou, M. (2012) · American Journal of Clinical Pathology · doi:10.1309/ajcp3k5vufalztkc · Cited by 60
Knudsen, K. E., & Kelly, W. K. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.33 · Cited by 67
Kron, K. J., Liu, L., Trudel, D., Pethe, V. V., Trachtenberg, J., Fleshner, N. E., Bapat, B. V., & van der Kwast, T. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2901 · Cited by 69
Identification of Prognostic Biomarkers for Prostate Cancer
Kosari, F., Munz, J. M. A., Savci-Heijink, C. D., Spiro, C., Klee, E. W., Kube, D. M., Tillmans, L. S., Slezak, J. M., Karnes, R. J., Cheville, J. C., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1494 · Cited by 60
Zhang, Q., Liu, S., Zhang, Q., Xiong, Z., Wang, A. R., Myers, L., Melamed, J., Tang, W. W., & You, Z. (2014) · The Prostate · doi:10.1002/pros.22805 · Cited by 63
The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer
Zhao, S. G., Evans, J. R., Kothari, V., Sun, G. Y., Larm, A., Mondine, V., Schaeffer, E. M., Ross, A. E., Klein, E. A., Den, R. B., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1250 · Cited by 60
Metadata
- Authors
- Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., Lee, C., Montie, J. E., Shah, R. B., Pienta, K. J., Rubin, M. A., & Chinnaiyan, A. M.
- Affiliations
- University of Michigan (US)
- Department of Pathology, University of Michigan Medical School, 1301 Catherine Street, Ann Arbor, MI 48109–0602, USA.
- Corresponding author
- Chinnaiyan, Arul M.
- ORCID
- Venue
- Science
- Published
- 2005-10-28
- Volume
- 310
- Issue
- 5748
- Pages
- 644-648
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2121158863
- Cited by
- 3,846
- References
- 32
- Citations by year
- 2026: 77 · 2025: 99 · 2024: 82 · 2023: 108 · 2022: 137 · 2021: 163 · 2020: 187 · 2019: 172 · 2018: 178 · 2017: 218 · 2016: 209 · 2015: 244 · 2014: 271 · 2013: 309 · 2012: 279
- FWCI
- 114.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (R01AG021404, R01 AG 21404)
- National Cancer Institute (UO1 CA111275-01, P50-CA-69568, U01CA111275, R01CA097063, R01 CA97063, 5P30 CA 46592, P50CA069568, P30CA046592)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- TMPRSS2-ERG fusion, prostate cancer, ETS transcription factors, chromosomal rearrangements, gene fusion, molecular diagnosis
- MeSH terms
- Transcriptional Regulator ERG, Androgens, DNA-Binding Proteins, Humans, Male, Membrane Proteins, Molecular Sequence Data, Neoplasm Proteins, Prostatic Neoplasms, Serine Endopeptidases, Transcription Factors, Translocation, Genetic, Gene Rearrangement, Oncogene Proteins, Fusion, Trans-Activators, Gene Expression Regulation, Neoplastic, Polymerase Chain Reaction, In Situ Hybridization, Fluorescence, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.